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Abstract 
Background: The concept of control is gaining importance in the field of allergic rhinitis (AR), with a visual analogue 
scale (VAS) score being a validated, easy and attractive tool to evaluate AR symptom control. The doctors’ perception 
of a VAS score as a good tool for evaluating AR symptom control is unknown, as is the level of AR control perceived by 
physicians who treat patients.
Methods: 307 voluntarily selected physicians attending the annual (2013) European Academy of Allergy and Clini-
cal Immunology (EAACI) meeting completed a digital survey. Delegates were asked to (1) estimate how many AR 
patients/week they saw during the season, (2) estimate the proportion of patients they considered to have well-, 
partly- and un-controlled AR, (3) communicate how they gauged this control and (4) assess how useful they would 
find a VAS as a method of gauging control. 257 questionnaires were filled out completely and analysed.
Results: EAACI delegates reported seeing 46.8 [standard deviation (SD) 68.5] AR patients/week during the season. 
They estimated that 38.7 % (SD 24.0), 34.2 % (SD 20.2) and 20.0 % (SD 16.34) of their AR patients had well-controlled 
(no AR symptoms), partly-controlled (some AR symptoms), or un-controlled-(moderate/severe AR symptoms) disease 
despite taking medication [remainder unknown (7.1 %)]. However, AR control was assessed in many ways, including 
symptom severity (74 %), frequency of day- and night-time symptoms (67 %), activity impairment (57 %), respiratory 
function monitoring (nasal and/or lung function; 40 %) and incidence of AR exacerbations (50 %). 91 % of delegates 
felt a simple VAS would be a useful tool to gauge AR symptom control.
Conclusions: A substantial portion of patients with AR are perceived as having uncontrolled or partly controlled 
disease even when treated. A simple VAS score is considered a useful tool to monitor AR control.
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Background
Control of disease is considered one of the key outcomes 
in several medical domains. Although the concept of 
control is well-defined in asthma, chronic obstructive 
pulmonary disease and other conditions such as glycae-
mic control in diabetes, [1] it has only recently gained 
significant attention in the field of allergic rhinitis (AR) 
[2–5]. Indeed, the patients’ evaluation of disease control 
by any type of treatment, leading to a significant reduction 
of symptom severity, has become one of the novel goals 
of treatment in different chronic diseases. In AR, there 
is growing consensus that a visual analogue scale (VAS) 
score represents a simple, good and valid tool to moni-
tor AR disease control [2, 6]. In 2010, Bousquet and col-
leagues [7] proposed a simple VAS to evaluate AR control. 
More sophisticated means of monitoring AR control have 
been used without showing superiority of one over the 
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other [8]. Therefore, a VAS has been incorporated into the 
treatment algorithms for AR [2] to guide treatment deci-
sions as part of an integrated care pathway [9]. It has yet 
to be validated in children. Nowadays, a digital version of 
the AR control VAS will be rolled out to patients, pharma-
cists and physicians to encourage better communication 
(with patients) and referral when appropriate. Physicians 
of all specialities involved in AR management can use the 
same VAS, from general practitioners (GPs) and allergists, 
to ear nose and throat (ENT) specialists, paediatricians, 
pulmonologists and dermatologists.
A VAS for AR has been shown to assess disease sever-
ity according to the Allergic Rhinitis and its Impact on 
Asthma (ARIA)-guidelines, with a VAS cut off score of 
50 mm distinguishing between mild and moderate/severe 
AR in adults [10]. The VAS score incorporates quality 
of life (QoL) and reflective total nasal symptom score 
(rTNSS) [11] and correlates with improvements in AR 
symptoms and QoL. It can be used to assess AR severity 
in both intermittent and persistent disease in untreated 
or treated patients [10]. A change in VAS score of more 
than 23  mm represents clinically relevant changes in 
QoL and AR symptoms, possibly reflecting a response to 
treatment [6].
The major gaps in the current appreciation of VAS as a 
tool for the evaluation of symptom control are the follow-
ing: (1) the level of control reached in patients by actual 
treatment options as perceived by the medical doc-
tors, (2) how disease control is evaluated, and (3) physi-
cian perception on the usefulness of a VAS score for the 
evaluation of symptom control. Physicians often under-
estimate disease severity and impact on patients’ lives, 
while at the same time over-estimate the effectiveness 
of treatment [12, 13]. Physician-patient communication 
is greatly hampered by a lack of a common language to 
describe AR control and a lack of a universally-accepted 
definition of what AR control actually means. The aim 
of this exploratory study was to assess how physicians 
measure AR symptom control, how they perceive the 
control status of their patients and how they regard the 
usefulness of a VAS to gauge disease control.
Methods
A quantitative, digital survey, designed to collect views 
of physicians who treat AR routinely in clinical prac-
tice, was carried out during the 32nd EAACI Congress 
(Milan, Italy) from 22nd to 26th June 2013. The survey 
content was informed by experts in the field of AR (JB, 
CB and DP) and conducted at the Meda booth by phy-
sicians attending the exhibition (see Additional file  1). 
There was no incentive to take part in the survey.
Those who consented to take part had their EAACI 
barcode scanned, were allocated a digital ID and were 
provided with the survey questions on an iPad. Responses 
to all questions were anonymised and stored on an inde-
pendent server.
Delegates were asked to:
1. Estimate how many AR patients they saw per week 
during the season,
2. estimate the proportion of their patients they consid-
ered to have well-, partly- and un-controlled disease,
3. communicate how they gauged this control (>1 
answer permitted)
4. assess how useful they would find a VAS as a method 
of gauging control.
A representation of a VAS with marker slider was 
shown to delegates when considering their response to 
question 4. Survey questions and representation of the 
VAS with marker slider are provided in Additional file 1.
Descriptive statistics (mean and standard deviation) 
were used to summarise survey responses.
Results
307 EAACI 2013 delegates from 60 different countries 
and from different specialties (e.g. GPs, allergists, ENT 
specialists and paediatricians) completed the survey. 
Valid question responses were obtained for 257 of these. 
Surveys from 50 delegates were not included as they were 
incomplete.
On average, respondents reported seeing 46.8 [stand-
ard deviation (SD) 68.5] AR patients/week during the 
season. They estimated that AR was well-controlled, 
partly-controlled and un-controlled in 38.7 % (SD 24.0), 
34.2  % (SD 20.2) and 20.0  % (SD 16.34) of patients, 
respectively, and unknown for the remainder (7.1  %). 
Delegates reported assessing disease control in many 
different ways, including symptom severity (74  %), fre-
quency of day- and night-time symptoms (67  %), activ-
ity impairment (57  %), respiratory function monitoring 
(nasal and/or lung function; 40  %) and incidence of AR 
exacerbations (50 %) (Fig. 1). 91 % of delegates felt that a 
VAS was a useful tool to assess disease control.
Discussion
According to 257 EACCI 2013 delegates, the VAS score 
is a useful tool to monitor disease control in AR. More 
than 50 % of AR patients were considered by physicians 
to have partly-controlled or uncontrolled disease, with 
many different features of AR, unrelated to nasal symp-
toms, determining physicians’ perception of disease of 
control. This observation that  >50  % of their patients 
have sub-optimal AR control is in agreement with other 
surveys [13–15]. The physicians’ perception of reach-
ing a good level of control in 38.7  % of patients also 
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corresponds well with previous reports: A European sur-
vey found that, according to physician assessment, good 
control of nasal and ocular symptoms was achieved in 
45.4 and 51.3 % of patients, respectively [13].
It was also apparent that AR control was assessed 
in multiple ways with no consensus on an optimal 
method. Of note was the large standard deviation seen 
around control perception, which shows a wide-ranging 
response to the question. Interestingly, the determinants 
of control as perceived by the physicians varied from fre-
quency of day- and night-time symptoms to respiratory 
function monitoring (nasal and/or lung function). One 
of the most striking findings was the extra-nasal symp-
toms, like frequency of day- and night-time symptoms 
and impaired activity being reported as key determinants 
of AR control.
91 % of the EAACI delegates who completed this sur-
vey agreed upon the validity of a VAS as a useful tool for 
assessing AR control. In our opinion, it is an intuitive tool 
for use in clinical studies, and by physicians and patients 
every day. The VAS is well suited to the task of assessing 
AR control. It is simple and quick to complete, incorpo-
rating assessment of both AR symptoms and quality-of-
life [11]. It correlates well with recognized randomized 
controlled trial endpoints [16], can discriminate accord-
ing to severity [10] and assess efficacy of treatments [16, 
17]. The VAS has also been used to assess effectiveness of 
treatments in real-life [18] as well as inadequacies of oth-
ers (including multiple treatments) [19].
Limitations of this survey relate to the fact that the 
most respondents were specialists (although with expe-
rience in treating AR), with relatively few GPs included. 
Delegates were not provided with an alternative control 
tool choice and also completed the survey at the Meda 
booth, which may have introduced bias. However, no 
financial or any other incentive was given to complete 
the survey. Also delegate speciality was not consistently 
recorded which may have yielded interesting insights into 
how AR control is assessed across specialities. Finally, 
information on what proportion of AR patients had con-
comitant asthma was not captured. This would have pro-
vided important information on how disease control was 
assessed and whether the perception of control was bet-
ter or worse for those patients with co-morbid disease.
The VAS will form the basis of a new contre les MAla-
dies Chronique pour un VIeillissement Actif (MACVIA)-
ARIA AR app directed at patients called ‘Allergy Diary’ 
which is now available for free download in many Euro-
pean countries. Users can assess their disease control daily 
by simply clicking on the VAS in response to the question 
‘overall how much are your allergic symptoms bother-
ing you today?’, from ‘not at all bothersome’ to ‘extremely 
bothersome’. VAS scores are logged and plotted over time 
with control assessed as well-, partly- and un-controlled, 
according to specific VAS score cut-offs. The VAS will 
also be incorporated into a companion app for healthcare 
providers as well as into the new AR guideline, and used 
to guide treatment decisions. Moving to a digital VAS is 
attractive since in real life, on paper, VAS scores are often 
wrongly completed by the patient, even after explanation; 
either by failing to cross the line, putting a cross above or 
below it or writing a figure. An electronic version would 
prevent such errors. However, it may not allow for com-
plexity of response such as persistence of a problemati-
cal co- morbidity despite good control of AR. The overall 
aim of ‘Allergy Diary’, the Allergy Diary companion app 
and the updated AR guideline (and the VAS contained 
within them) is to facilitate a top down communication, 
from guidelines to healthcare providers to patients, allow-
ing doctors to more easily comply with the guidelines, to 
better tailor AR medications to patients’ needs and enable 
patients to better communicate their needs.
In short, a common language of AR disease control 
is needed. A simple VAS to measure and assess disease 
control could meet this need and is welcomed by physi-
cians. It should enable us to move from the illusion to the 
confirmation of communication.
Additional file
Additional file 1. Survey questions. The questions asked in a quantita-
tive, digital survey carried out during the 32nd EAACI Congress (Milan, 
Italy) from 22nd to 26th June 2013.The survey was designed to collect 
views of physicians who treat AR routinely in clinical practice. It includes 
a representation of a VAS with maker slider that was shown to delegates 
when considering their response to question 9 of the survey.
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Fig. 1 Methods used by EAACI 2013 meeting delegates to assess 
AR symptom control. Respiratory function monitoring refers to nasal 
and/or lung function
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